Emcure Pharmaceuticals Crescita futura
Future criteri di controllo 4/6
Emcure Pharmaceuticals is forecast to grow earnings and revenue by 27.1% and 11.4% per annum respectively. EPS is expected to grow by 26.1% per annum. Return on equity is forecast to be 19.4% in 3 years.
Informazioni chiave
27.1%
Tasso di crescita degli utili
26.1%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 18.4% |
| Tasso di crescita dei ricavi | 11.4% |
| Rendimento futuro del capitale proprio | 19.4% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 07 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Nessun aggiornamento
Recent updates
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2027 | 97,472 | 11,508 | 10,126 | N/A | 3 |
| 3/31/2026 | 88,168 | 9,529 | 9,908 | N/A | 3 |
| 3/31/2025 | 79,516 | 7,471 | 5,722 | N/A | 3 |
| 6/30/2024 | 69,172 | 5,119 | N/A | N/A | N/A |
| 3/31/2024 | 66,583 | 4,982 | 7,901 | 10,972 | N/A |
| 12/31/2023 | 65,361 | 5,493 | 7,670 | 11,046 | N/A |
| 9/30/2023 | 64,139 | 6,003 | 7,439 | 11,120 | N/A |
| 6/30/2023 | 61,464 | 5,532 | N/A | N/A | N/A |
| 3/31/2023 | 59,858 | 5,320 | 3,435 | 7,469 | N/A |
| 3/31/2022 | 58,554 | 6,622 | 3,712 | 7,682 | N/A |
| 3/31/2021 | 50,335 | 5,808 | 5,588 | 7,044 | N/A |
| 3/31/2020 | 50,486 | 836 | 3,457 | 5,003 | N/A |
| 3/31/2019 | 47,172 | 1,893 | 656 | 4,826 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: EMCURE's forecast earnings growth (27.1% per year) is above the savings rate (6.7%).
Guadagni vs Mercato: EMCURE's earnings (27.1% per year) are forecast to grow faster than the Indian market (18.1% per year).
Guadagni ad alta crescita: EMCURE's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: EMCURE's revenue (11.4% per year) is forecast to grow faster than the Indian market (10.2% per year).
Ricavi ad alta crescita: EMCURE's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: EMCURE's Return on Equity is forecast to be low in 3 years time (19.4%).